Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMENTUM: Symbravo (AXS-07) in Acute Migraine
NCT03896009Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin + saxagliptin in migraine, sponsored by Axsome Therapeutics, Inc.. Started Mar 2019; status: completed.
02
Drugs
dapagliflozin + saxagliptin
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03896009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896009.